Business Context and Reporting Period
This Form 8-K Current Report was filed by Boston Scientific Corporation on November 18, 2025. The filing details the Board of Directors' approval of new executive compensation plans effective for the performance year beginning January 1, 2026. The report does not contain financial results for a specific reporting period but focuses on governance and compensation structure updates.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a current report regarding corporate governance and compensation arrangements rather than a financial results report.
Material Changes and Compensation Plans
The Board approved three new compensation programs for 2026, which are substantially similar to 2025 plans but updated for the new performance cycle:
- 2026 Annual Bonus Plan:
- Covers eligible exempt and nonexempt personnel, including named executive officers.
- Includes an aggregate bonus pool and a dynamic bonus pool (up to 10% of total target bonuses).
- Company-wide distribution percentage (0% - 150%) is based on global sales, adjusted earnings per share, operating income, and sustainability goals.
- Individual performance modifiers (0% - 150%) allow for a maximum payout potential of 225% of the target bonus.
- Subject to discretionary recoupment and Dodd-Frank Clawback policies.
- 2026 Relative Total Shareholder Return (rTSR) Performance Share Program:
- Measures performance over a three-year period (Jan 1, 2026 – Dec 31, 2028).
- Compares Boston Scientific's Total Shareholder Return (TSR) against the S&P 500 Healthcare Index.
- Award range is 0% to 200% of the target number of awards based on TSR rank.
- Awards are granted as restricted stock units and are subject to forfeiture if employment terminates due to retirement prior to January 1, 2027.
- 2026 Organic Net Sales Growth Performance Share Program:
- Measures performance over a three-year period (Jan 1, 2026 – Dec 31, 2028).
- Compares organic net sales growth (excluding foreign currency and certain M&A impacts) against the financial plan.
- Award range is 0% to 200% of the target number of awards.
- Similar forfeiture rules apply regarding retirement prior to January 1, 2027.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or outlook for future periods. However, it highlights the following risks and contingencies related to compensation:
- Clawback and Recoupment: All executive awards under these plans are subject to the Company's discretionary recoupment policy and Dodd-Frank Clawback Policy. The Company may seek reimbursement or recovery of awards in cases of executive misconduct, gross dereliction of duty, or material policy violations causing significant harm.
- Performance Discretion: The Board retains discretion to terminate, suspend, or modify the bonus plans and reduce distribution percentages based on quality objectives and system performance.
- Forfeiture Risk: Performance share awards are subject to forfeiture if a participant retires before January 1, 2027.
Investor Verification Checklist
- Verify the specific performance thresholds for "global sales," "adjusted earnings per share," and "operating income" in the full text of the 2026 Annual Bonus Plan (Exhibit 10.1).
- Review the definition of "organic net sales" in Exhibit 10.3 to understand exclusions regarding acquisitions and divestitures.
- Confirm the composition of the S&P 500 Healthcare Index used for the rTSR comparison in Exhibit 10.2.
- Assess the potential financial impact of the dynamic bonus pool (up to 10% of total target bonuses) on future compensation expenses.
- Monitor future filings for the actual grant dates and target award numbers for executive officers under these new programs.